Tilray Brands' Profitability: Tilray Brands reported a net income of $1.5 million in Q1 fiscal 2026, a significant turnaround from a net loss of $34.7 million in the same quarter last year, driven by cost control and operational efficiency.
Verano's Revenue Challenges: Verano Holdings is experiencing revenue pressure due to a competitive U.S. market, with a 300 basis point contraction in gross margin to 47% in Q3 2025, despite a 13% reduction in SG&A expenses.
Aurora Cannabis Growth: Aurora Cannabis saw a 37% year-over-year increase in its medical cannabis segment sales, reaching nearly $65 million in Q1 fiscal 2026, supported by higher prices and improved production efficiencies.
Tilray's Stock Performance: Over the past six months, Tilray's shares have surged by 125.2%, significantly outperforming the industry, while currently trading at a forward Price-to-Sales ratio of 1.35X compared to the industry average of 3.16X.
Wall Street analysts forecast ACB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is 4.32 USD with a low forecast of 4.32 USD and a high forecast of 4.32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ACB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is 4.32 USD with a low forecast of 4.32 USD and a high forecast of 4.32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 4.330
Low
4.32
Averages
4.32
High
4.32
Current: 4.330
Low
4.32
Averages
4.32
High
4.32
No data
About ACB
Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The Company also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
